The diagnostic chain’s net profit declined 15.2% year-on-year to ₹131.3 crore versus ₹154.8 crore in the same period last year.
However, revenue rose 16.6% to ₹702.7 crore from ₹602.6 crore, indicating healthy volume growth and steady demand across its test portfolio.
EBITDA increased 11% year-on-year to ₹186.8 crore compared to ₹169 crore earlier, though margins slipped to 26.6% from 28% in the year-ago period, reflecting cost pressures despite topline expansion.
The board has recommended a final dividend of ₹4 per equity share (40% on a face value of ₹10) for the financial year ended March 31, 2026, subject to shareholder approval at the upcoming AGM.
The record date for dividend eligibility has been fixed as June 26, 2026.
Additionally, the board has approved the re-appointment of (Hony) Brig. Dr. Arvind Lal, Padma Shri (DIN: 00576638), as Executive Chairman and Whole-Time Director for a period of five consecutive years commencing April 1, 2027, subject to shareholders’ approval at the ensuing AGM.
Shares of Dr Lal PathLabs ended lower on Thursday, April 30, by 1.7% at ₹1,374.00 on the NSE.
Also Read: IndiaMART Q4 results: Profit plunges 72%, margins contract; ₹60 dividend announced
First Published: Apr 30, 2026 4:00 PM IST
